ALK-Abello A/S 2024 IR
The report highlights ALK's performance in 2024, delivering 15% sales growth in local currencies and a 65% increase in operating profit (EBIT) to DKK 1,091 million. The company launched its new Allergy+ strategy, expanding its addressable markets in respiratory allergy, anaphylaxis, and food allergy. Key achievements included the European paediatric approval of the ACARIZAX house dust mite tablet and a transformative licensing agreement for the neffy adrenaline nasal spray. On sustainability, ALK had its absolute CO2 reduction targets validated by the Science Based Targets initiative, aiming for a 42% reduction in Scope 1 and 2 emissions by 2030.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2024
Type: IR
Pages: 167
ALK-Abello A/S
The report highlights ALK's performance in 2024, delivering 15% sales growth in local currencies and a 65% increase in operating profit (EBIT) to DKK 1,091 million. The company launched its new Allergy+ strategy, expanding its addressable markets in respiratory allergy, anaphylaxis, and food allergy. Key achievements included the European paediatric approval of the ACARIZAX house dust mite tablet and a transformative licensing agreement for the neffy adrenaline nasal spray. On sustainability, ALK had its absolute CO2 reduction targets validated by the Science Based Targets initiative, aiming for a 42% reduction in Scope 1 and 2 emissions by 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees